Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Pharma Equity Group – Opdatering på 1. Kvartal 2024

PEG16.05.2024, 11.00
HC Andersen Capital

Mød og stil spørgsmål til CEO Thomas K. Selsø fra Pharma Equity Group torsdag den 16. maj 2024 kl. 11:00, som vil gennemgå 1. kvartal 2024 samt større begivenheder efter afslutningen af kvartalet.

Pharma Equity Group, har fokus på repositionering af eksisterende API’er (Aktive farmaceutiske ingredienser) til andre indikationer. Pharma Equity Group erhvervede en større portefølje fase 2 projekter i forbindelse med køb af Reponex, indenfor større sygdomsområder. Herunder bakteriel peritonitis (bughindebetændelse), kroniske hudsår, inflammatoriske tarmsygdomme samt tyk- og endetarmskræft. Selskabet arbejder med partnerskabsstruktur for alle sine projekter i fase 3.

Disclaimer: HC Andersen Capital modtager betaling fra Pharma Equity Group for en Digital IR/Corporate Visibility abonnementsaftale. /Claus Thestrup kl. 09.14 17.04.2024.

Upcoming webcasts

Recent videos

HCA Morgenbørs 02/10 - Fokus på Saga Furs i Interview med Michael Hove fra Scandinavian Investment Group
02.10.2026, 09.32 NKT
B&O: CFO-interview i forbindelse med Q1 2026/27
01.10.2026, 16.14 Bang & Olufsen
HCA Morgenbørs 01/10 - Interview med Mohammad Lauritzen fra Fibo Invest og udsigt til en negativ åbning
01.10.2026, 09.36 Pandora
From Oil to Chips: 56 Years of the World's Most Valuable Companies
30.09.2026, 14.54 Nvidia
First Date with a Company – What Does the Company Actually Do? | Femme x Nordea Portfolio Managers 07
30.09.2026, 13.52 Nordea
View all videos